[2023. 10. 27.][NASDAQ:ALNY]Alnylam Recognized by Science Magazine as Top Employer for Fifth Consecutive Year
Alnylam Pharmaceuticals Ranks Third in Science Magazine’s Top Employer Survey for 2023
CAMBRIDGE, Mass.–(BUSINESS WIRE)– In a surprising turn of events, Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, has secured the third position in Science magazine’s Top Employer Survey for 2023. This marks the fifth consecutive year that Alnylam has been recognized as one of the top employers in the industry, surpassing expectations.
“As a company deeply rooted in scientific innovation, it is paramount for us to be recognized as a premier workplace for individuals seeking a fulfilling career in a cutting-edge scientific environment,” stated Dr. Kevin Fitzgerald, Chief Scientific Officer at Alnylam. “Equally crucial is our commitment to fostering a workplace culture that empowers all our employees to excel while advancing our mission to deliver groundbreaking RNAi therapies to patients. This consistent acknowledgment by Science magazine reaffirms our dedication to providing an exceptional work environment.”
The annual survey, which gathered input from over 6,800 professionals spanning the biotechnology, biopharmaceutical, and related industries, evaluated companies based on 24 key attributes. These included criteria such as innovative leadership, respect for employees, and social responsibility, reflecting Alnylam’s core values.
Among the standout attributes that propelled Alnylam to its top-three ranking were its commitment to “Treating employees with respect,” being “Socially responsible,” and maintaining a “Work culture aligned with employees’ personal values.”
Alnylam Pharmaceuticals continues to lead the way in translating RNA interference (RNAi) into revolutionary medicines with the potential to address unmet needs in rare and prevalent diseases. Leveraging Nobel Prize-winning science, RNAi therapeutics offer a clinically proven approach to developing transformative medicines. The company’s portfolio includes commercial RNAi therapeutic products like ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and Leqvio® (inclisiran), which is being developed and marketed in partnership with Novartis. Alnylam’s robust pipeline comprises numerous late-stage investigational medicines, underscoring its commitment to delivering impactful treatments in both rare and common diseases on a global scale.
Alnylam’s headquarters are located in Cambridge, MA. To learn more about their pioneering work, scientific initiatives, and promising pipeline, please visit www.alnylam.com. You can also connect with them on X (formerly Twitter) at @Alnylam, LinkedIn, or Instagram.
View the source version on businesswire.com: https://www.businesswire.com/news/home/20231026365139/en/
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)
+1-617-682-4340
Josh Brodsky
(Investors)
+1-617-551-8276
Source: Alnylam Pharmaceuticals, Inc.